VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 100 filers reported holding VERONA PHARMA PLC in Q3 2023. The put-call ratio across all filers is 3.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,540 | -22.9% | 892 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $18,857 | +5.3% | 892 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $17,911 | -23.2% | 892 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $23,308 | +159.0% | 892 | 0.0% | 0.00% | +50.0% |
| Q3 2022 | $9,000 | +125.0% | 892 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $4,000 | 0.0% | 892 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $4,000 | -33.3% | 892 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $6,000 | +20.0% | 892 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $5,000 | – | 892 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |